147776-37-2

Basic information

• Product Name: 5-n-butyl-4-[[2'-[N-(2-chlorobenzoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-(2-chloro-5-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
• Synonyms: 5-n-butyl-4-[[2'-[N-(2-chlorobenzoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-(2-chloro-5-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
• CAS NO: 147776-37-2
• Molecular Weight: 680.568
• Mol File: 147776-37-2.mol

Chemical Properties

• CAS DataBase Reference: 5-n-butyl-4-[[2'-[N-(2-chlorobenzoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-(2-chloro-5-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-n-butyl-4-[[2'-[N-(2-chlorobenzoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-(2-chloro-5-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one(147776-37-2)
• EPA Substance Registry System: 5-n-butyl-4-[[2'-[N-(2-chlorobenzoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-(2-chloro-5-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one(147776-37-2)

Safety Data

• Hazardous Substances Data: 147776-37-2(Hazardous Substances Data)

Upstream product

• 118-91-2 ortho-chlorobenzoic acid 
• 146949-05-5 5-n-butyl-2-(2-chloro-5-nitrophenyl)-2,4-dihydro-4-<(2'-sulfamoylbiphenyl-4-yl)methyl>-3H-1,2,4-triazol-3-one 
• 146949-06-6 ethyl N-carbethoxy-valerimidate 
• 67333-74-8 1-(2-chloro-benzoyl)-1H-imidazole 
• 159547-15-6 2-(2-bromo-5-nitrophenyl)-4-<<2'-(N-tert-butylsulfamoyl)biphenyl-4-yl>methyl>-5-n-butyl-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 159547-14-5 2-(2-bromo-5-nitrophenyl)-5-n-butyl-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 146949-03-3 5-n-butyl-2-(2-chloro-5-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 100367-78-0 (2-bromo-5-nitrophenyl)hydrazine 
• 96701-59-6 (2-chloro-5-nitrophenyl)hydrazine 

Downstream Products

• 147776-38-3 2-(5-amino-2-chlorophenyl)-5-n-butyl-4-[[2'-[N-(2-chlorobenzoyl)sulfamoyl]biphenyl-4-yl]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 

Relevant articles and documents

Triazolinone Biphenylsulfonamides as Angiotensin II Receptor Antagonists with High Affinity for Both the AT1 and AT2 Subtypes

Angiotensin II (AII), the endogenous peptide ligand of the AII receptor, has equivalent high affinity for both the AT1 and AT2 receptor subtypes while most of the reported nonpeptide AII antagonists are AT1-selective.In an